
Sign up to save your podcasts
Or
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatment.
Read the article: http://dx.doi.org/10.1136/lupus-2022-000761
3.9
1414 ratings
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatment.
Read the article: http://dx.doi.org/10.1136/lupus-2022-000761
11,162 Listeners
41 Listeners
5 Listeners
49 Listeners
7 Listeners
5 Listeners
3 Listeners
3 Listeners
3 Listeners
10 Listeners
39 Listeners
14 Listeners
1 Listeners
48 Listeners
1 Listeners
6 Listeners
497 Listeners
281 Listeners
3,331 Listeners
3 Listeners
90 Listeners
24 Listeners
1,105 Listeners
1,673 Listeners
23 Listeners
349 Listeners
23 Listeners
32 Listeners
367 Listeners
43 Listeners
2 Listeners
0 Listeners
0 Listeners
2 Listeners